Archer Materials Limited (ASX: AXE) has announced the successful development of a miniaturized version of its Biochip graphene field effect transistor (gFET) chip. This advancement, achieved through a redesign of circuit layouts, enables the fabrication of smaller gFET chips for commercial use.
The new gFET chip design boasts a significant reduction in size, shrinking from 10mm x 10mm to 1.5mm x 1.5mm. This improvement promises more efficient production, with a four-inch wafer expected to yield 1375 chips compared to the previous 45 chips. The fabrication process will be handled by Applied Nanolayers (ANL) in the Netherlands, with delivery anticipated in the first half of 2024.
Dr. Mohammad Choucair, CEO of Archer, expressed satisfaction with the achievement, highlighting the company’s expertise in gFET chip design. Collaboration with partners such as Applied Nanolayers and AOI Electronics in Japan has been instrumental in realizing this milestone.
The miniaturized gFET chip design represents a significant advancement in Archer’s Biochip innovation, aimed at integrating gFETs into advanced fluidic systems for miniaturized lab-on-a-chip platforms. This development holds potential benefits for medical diagnostics, enabling parallelized detection of biologically relevant targets on a single chip.
Archer Materials continues to strengthen its relationships with global foundry partners, underscoring its commitment to semiconductor innovation. With the delivery of packaged chips expected in mid-2024, Archer is poised to make notable contributions to the fields of medical diagnostics and quantum computing.
